Alström Syndrome Genetics: A Clinician's Guide

This article provides a technical overview of ALMS1 genetics for healthcare professionals — pediatricians, subspecialists, residents, medical students, and genetic counselors who may encounter Alström Syndrome in their practice. It covers the gene structure, protein function, mutation spectrum, ciliary biology, animal models, and current research directions.

ALMS1 is located at chromosome 2p13.1 and spans approximately 224 kb of genomic DNA. The gene contains 23 exons, with most of the coding sequence concentrated in exons 8, 10, and 16. The mRNA is approximately 12.9 kb in length, encoding a protein of 4,169 amino acids.¹

The ALMS1 protein has several recognizable domains:

• An N-terminal region containing several proline-rich motifs
• A series of tandem repeats (referred to as ALMS motifs) clustered in exon 8
• A C-terminal region containing motifs that mediate centrosomal targeting

The protein is large, predominantly disordered in its primary structure, and lacks well-characterized enzymatic activity. Its function is largely structural and scaffolding rather than catalytic.²

ALMS1 has two principal subcellular locations:

1. The basal body of primary cilia. ALMS1 is recruited to the basal body and the ciliary transition zone, where it participates in ciliary biogenesis, intraflagellar transport, and signal transduction. 2. Centrosomes. ALMS1 also localizes to centrosomes during cell division and likely contributes to centrosomal integrity and function.

Functional roles attributed to ALMS1 in different contexts include:

• Regulating ciliary length and stability
• Modulating Hedgehog signaling (which depends on functional cilia)
• Participating in actin organization and endosomal recycling
• Contributing to the regulation of insulin signaling in adipocytes and pancreatic beta cells

ALMS1 is widely expressed in adult and developing tissues, including the retina, cochlea, kidney, heart, hypothalamus, adipose tissue, and pancreas — explaining the multisystem phenotype.³

Across published cohorts, the ALMS1 mutation distribution is dominated by truncating variants:

• Nonsense mutations — approximately 47%
• Frameshift mutations — approximately 45%
• Splice-site mutations — approximately 3%
• Missense mutations — approximately 2%
• Larger structural deletions — approximately 2–3%

Hotspot regions include exons 8, 10, and 16, which together account for the majority of pathogenic variants. The very high frequency of truncating variants reflects the large size of the gene (which presents many opportunities for nonsense mutations) and the apparent intolerance of the protein to truncation.⁴

The 2025 Chinese cohort study of 127 patients identified 64 novel ALMS1 variants, indicating that the mutation spectrum continues to expand and that gene-specific variant databases need ongoing curation.⁵

Large cohort studies have looked for genotype-phenotype correlations with limited success. Key observations:

• The classical multisystem phenotype is consistent across the majority of patients regardless of specific variants
• Some studies have suggested mutations in the C-terminal region may correlate with milder cardiac disease, but findings have not been consistently replicated
• Even within families with identical variants (e.g., siblings), clinical course varies significantly
• The age of onset and severity of complications appear to be modulated by environmental and genetic background factors not yet identified⁶

This means specific variants are useful for diagnostic confirmation, family planning, and (eventually) variant-specific therapy, but not currently for individual prognostication.

Alström is autosomal recessive. Standard recurrence risk applies:

• Carrier × carrier — 25% affected, 50% carrier, 25% non-carrier per pregnancy
• Affected × carrier — 50% affected, 50% carrier per pregnancy
• Affected × non-carrier — 100% obligate carrier, 0% affected per pregnancy

Carrier frequency in the general population is not precisely known but is estimated to be on the order of 1 in 500 to 1 in 1,000 based on disease prevalence (~1 in 1,000,000).

Consanguinity increases the risk of homozygous mutations from a shared ancestor. In some founder populations (Acadian descendants, certain communities in Turkey, Pakistan, Italy), specific variants are enriched.

Recommended testing approaches:

When clinical suspicion is high

• Targeted ALMS1 sequencing (sequencing all exons plus splice junctions)
• Add deletion/duplication analysis (CNV testing) to capture larger structural variants

When the differential includes related conditions

• Multi-gene panel covering ciliopathies, retinal dystrophies, or pediatric cardiomyopathies
• Most modern panels include ALMS1 alongside BBS genes, Usher genes, and others

When initial testing is non-diagnostic but suspicion remains high

• Re-examine sequencing for missed variants in regions of low coverage
• Add deletion/duplication analysis if not previously done
• Consider whole-exome or whole-genome sequencing
• Consider mRNA-based studies for splicing analysis if a splice-site variant is suspected

Special situations

• Critically ill infants — rapid trio whole-genome sequencing programs can return preliminary results within days, enabling diagnosis during the initial NICU/PICU admission
• Adult-onset diagnosis — patients diagnosed with separate conditions (cardiomyopathy, retinitis pigmentosa, severe insulin resistance) may benefit from comprehensive panel-based testing if the multisystem pattern emerges retrospectively⁷

Following ACMG/AMP guidelines, variant interpretation in ALMS1 benefits from:

• PVS1 (null variant in a gene where loss of function is a known mechanism) — applies broadly given the dominance of truncating variants
• PM2 (absent from controls) — applicable for many novel variants given the rarity of the syndrome
• PM3 (detected in trans with a pathogenic variant) — particularly useful when both variants are identified in an affected proband
• PP3 / BP4 (computational prediction) — applied with caution for missense variants

VUSs are common in ALMS1 given the size of the gene. Reanalysis with additional segregation data, additional cohort cases, or functional evidence often reclassifies VUSs over time.

Alms1 knockout mouse models recapitulate many features of human Alström — retinal degeneration, obesity, insulin resistance, and cardiac dysfunction — making them useful for therapeutic development.⁸ The fat aussie (foz) mouse line, with a spontaneous Alms1 mutation, has been particularly informative for metabolic studies.

Current research directions include:

• AAV-mediated gene therapy — challenging due to the large ALMS1 size, with ongoing work on dual-AAV strategies and minigene approaches
• CRISPR-Cas9 gene editing — under investigation, including in human-derived iPSC models
• Antisense oligonucleotides (ASOs) — for specific splice-site or amenable variants
• Pharmacological approaches targeting downstream pathways — particularly metabolic pathways
• Read-through agents for nonsense variants — being explored across multiple genetic conditions

For non-genetics clinicians who may encounter Alström:

• Photophobia + nystagmus + dilated cardiomyopathy in an infant is highly suggestive
• Cone-rod dystrophy + childhood obesity + early-onset T2DM is highly suggestive in an older child or adult
• Bardet-Biedl-like presentation without polydactyly or intellectual disability should prompt ALMS1 testing
• Dilated cardiomyopathy with retinal disease in any age group should prompt ALMS1 on the panel
• Severe insulin resistance with retinitis pigmentosa in an adult is worth ALMS1 panel review

The 2020 international consensus guidelines provide system-by-system surveillance recommendations once the diagnosis is confirmed.⁹

• Alström Syndrome Genetics: ALMS1 Gene Explained (Pillar)
• What Is the ALMS1 Gene?
• ALMS1 Mutations: Understanding Your Genetic Test Report
• Alström Syndrome Diagnostic Criteria
• Alström Syndrome Research and Clinical Trials in 2026

April 30, 2026.